EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)

Identity

Other names	**BP-1** **4EBP1** **4E-BP1** **PHAS-I** **MGC4316**
HGNC (Hugo)	**EIF4EBP1**
Location	8p12
Location_base_pair	Starts at 38007177 and ends at 38037040 bp from pter (according to hg18-Mar_2006) **[Mapping]**

DNA/RNA

Description The EIF4EBP1 gene codes for 4E-BP1, one member of a family of small proteins that act as repressors of translation. The gene is 29.86 Kb in length and contains three exons, comprising nucleotides 1-217, 218-397 and 398-859 of the mature mRNA.

Transcription Activity of the promoter of the EIF4EBP1 gene is regulated by the Forkhead-O1 (FOXO1) transcription factor (Southgate et al., 2007). Over-expression of FOXO1 enhances the levels of 4E-BP1 mRNA and protein. The consequent accumulation of the hypophosphorylated form of 4E-BP1 impairs overall protein synthesis. There is evidence that activity of the phosphatidylinositol 3-kinase (PI3K) and MAP kinase pathways can negatively regulate the transcription of EIF4EBP1 (Azar et al., 2008), possibly via the transcription factor Egr-1 (Rolli-Derkinderen et al., 2003). Conversely, EIF4EBP1 transcription is positively regulated by ATF4 in response to cell stress (Yamaguchi et al., 2008).

Pseudogene Two pseudogenes with homology to 4E-BP1 exist in the human genome, located at 14q11.2 (LOC768328) and 22q12 (EIF4EBP1P), with the latter pseudogene present on the antisense strand of the gene locus encoding chromodomain helicase DNA binding protein 8 (CHD8).

Protein



The diagram illustrates key regulatory features of the human 4E-BP1 protein, including the RAIP and TOS motifs that are important for the phosphorylation of the protein at Thr^{37}, Thr^{46}, Ser^{65}, Thr^{70} and Ser^{101} by the Raptor/mTOR complex (Eguchi et al., 2006; Lee et al., 2008). Additional phosphorylation sites have been identified at Ser^{83} and Ser^{112}. The region required for binding of 4E-BP1 to initiation factor eIF4E and a site of cleavage of the protein by caspases in apoptotic cells are also shown. (Diagram adapted from an original prepared by Dr C. Constantinou).

Description Human 4E-BP1 is a 118 amino acid protein (119 amino acids including the initiating methionine) and is encoded by an mRNA containing 877 nucleotides (including a short poly(A) tail). The mRNA has a 72 nucleotide 5' untranslated region and a 448 nucleotide 3' untranslated region. The coding region comprises nucleotides 73-429. The protein can be reversibly phosphorylated at Thr^{37}, Thr^{46}, Ser^{65}, Thr^{70}, Ser^{83}, Ser^{101} and Ser^{112} in response to a variety of physiological

stimuli.

Expression 4E-BP1 is ubiquitously expressed, although its presence is not essential to the viability of cells or the organism as a whole (Le Bacquer et al., 2007). The level of expression and state of phosphorylation of the protein may influence cellular phenotype, with high levels of phosphorylated 4E-BP1 in breast, ovary, and prostate tumours being associated with malignant progression and an adverse prognosis (Armengol et al., 2007). Conversely, hypophosphorylated 4E-BP1 may have an anti-oncogenic role due to its inhibitory effect on eIF4E.

Localisation 4E-BP1 is present in both cytoplasm and nucleus. The hypophosphorylated protein in the latter compartment can sequester eIF4E within the nucleus under conditions of physiological stress (Rong et al., 2008).

Function The members of the 4E-BP family of proteins act by binding to the mRNA cap-binding protein eukaryotic initiation factor 4E (eIF4E), in competition with another initiation factor, eIF4G, that is essential for polypeptide chain initiation. Thus the availability of eIF4E for translation of cap-dependent mRNAs is limited by the extent to which this factor is sequestered by the 4E-BPs. 4E-BP1 is reversibly phosphorylated at multiple sites (see diagram above), in response to several physiological signals that promote translation (Proud, 2004; Wang et al., 2005; Proud, 2006). Such phosphorylations lower the affinity of 4E-BP1 for eIF4E and result in the dissociation of the two proteins, thereby enhancing the level of active eIF4E and promoting the translation of capped mRNAs, most likely in a selective manner (Averous et al., 2008). Conversely, physiological stresses and other conditions that inhibit translation - e.g. exposure of cells to cytokines of the TNFalpha family (Lang et al., 2007; Jeffrey et al., 2006) or activation of the tumour suppressor protein p53 (Tilleray et al., 2006; Constantinou and Clemens, 2007) - cause dephosphorylation of 4E-BP1 and increase binding of the latter to eIF4E. 4E-BP1 is also susceptible to other post-translational modifications, notably specific proteolytic cleavages (Tee and Proud, 2002; Constantinou et al., 2008) and phosphorylation-dependent ubiquitination (Elia et al., 2008).

Although 4E-BP1 is not essential to viability the protein (together with its homologue 4E-BP2) is important for regulation of adipogenesis and insulin resistance (Le Bacquer et al., 2007). The 4E-BPs have also been reported to play a role in myelopoiesis (Olson et al., 2008). There is a major role for 4E-BP1 in the responses of cells to hypoxia, which promotes dephosphorylation of the protein (Koritzinsky et al., 2006; Connolly et al., 2006). It is likely that this response implements hypoxia-induced changes in gene expression at the translational level (Magagnin et al., 2008; Barnhart et al., 2008).

Homology 4E-BP1 was identified alongside another member of the eIF4E-binding protein family designated 4E-BP2 (Pause et al., 1994). A further homologue has also been identified, 4E-BP3 (Poulin et al., 1998), and these proteins respectively share 55.7% identity (82.0% similarity) and 50.8% identity (66.9% similarity) with 4E-BP1. All share the central eIF4E binding motif and are capable of competing with the eIF4G proteins for binding to eIF4E.

CLUSTAL 2.0.10 multiple sequence alignment:

```
4E-BP1  M S G G S S C S Q T P - - S R A I P A T R R V V L G D G V Q L P P G D Y S T T P G G T L F S T T P G G T R I I Y D R K F  58
4E-BP2  M S S S A G S G H Q P S Q S R A I P T - R T V A I S D A A Q L P - H D Y C T T P G G T L F S T T P G G T R I I Y D R K F  58
4E-BP3  M S T S T - - - - - - - - S C P I P - - - - - - - G G R D Q L P - D C Y S T T P G G T L Y A T T P G G T R I I Y D R K F  44
        * *   . :               *   . * *             . .     * * *       * . * * * * * * : : * * * * * * * * * * * * * *

4E-BP1  L M E C R N S P V T K T P P R D L P T I P G V T S P S S - - D E P P M E A S Q S H L R N S P E D K R A G G E E S Q F E M 116
4E-BP2  L L D R R N S P M A Q T P P C H L P N I P G V T S P G T L I E D S K V E V N N L N N L N N H D R K H A V G D D A Q F E M 118
4E-BP3  L L E C K N S P I A R T P P C C L P Q I P G V T T P - - - - - - P T A P L S K L E E L K E Q E T E E E I P D D A Q F E M  98
        * : :   : * * * : : : * * *     * *   * * * * * : *             .         . :   .     : .   :   : : .     : : : * * * *

4E-BP1  D I                                                                                                                 118
4E-BP2  D I                                                                                                                 120
4E-BP3  D I                                                                                                                 100
        * *
```

Mutations

Note No mutations have been identified.

Implicated in

Entity Breast cancer

Prognosis Elevated expression of eIF4E in human cancer often correlates with poor prognosis (Culjkovic et al., 2007). Likewise, expression of phosphorylated 4E-BP1 (which is inactive as an inhibitor of eIF4E) is associated with malignant progression and an

	adverse prognosis in breast, ovary, and prostate tumours (Armengol et al., 2007).
Oncogenesis	Because 4E-BP1 is an antagonist of the oncogenic initiation factor eIF4E (Avdulov et al., 2004), it might be anticipated that 4E-BP1 could function as a pro-apoptotic tumour suppressor protein. However it has been reported that a majority of large advanced breast cancers overexpress 4E-BP1 (Braunstein et al., 2007). The latter may contribute to tumourigenesis (in combination with overexpressed eIF4G) by promoting a hypoxia-activated switch in selective mRNA translation that enhances angiogenesis and tumour cell growth and survival.

Breakpoints

Note	Although no breakpoints within the 4E-BP1 gene locus have been identified, the chromosomal region containing 4E-BP1 (8p11-12) is frequently rearranged in breast carcinomas. However, microarray profiling of the genes within these regions in breast tumours and cell lines shows that rearrangements of the chromosome do not correlate with significantly changed 4E-BP1 mRNA expression (Gelsi-Boyer et al., 2005).

External links

	Nomenclature
HGNC (Hugo)	EIF4EBP1 3288
Entrez_Gene (NCBI)	EIF4EBP1 1978 eukaryotic translation initiation factor 4E binding protein 1
	Cards
Atlas	**EIF4EBP1ID40432ch8p12**
GeneCards (Weizmann)	EIF4EBP1
Ensembl (Hinxton)	ENSG00000187840 [Gene_View] EIF4EBP1 [Vega]
AceView (NCBI)	EIF4EBP1
Genatlas (Paris)	EIF4EBP1
euGene (Indiana)	1978
SOURCE (Stanford)	NM_004095
Gene Expression (Array Express)	ENSG00000187840
	Genomic and cartography
GoldenPath (UCSC)	EIF4EBP1 - 8p12 chr8:38007177-38037040 + 8p12 [Description] (hg18-Mar_2006)
Ensembl	EIF4EBP1 - 8p12 [CytoView]
Mapping of homologs : NCBI	EIF4EBP1 [Mapview]
OMIM	602223
	Gene and transcription
Gene : Genbank (Entrez)	AB044548 AK312011 BC004459 BC058073 BF964628
Reference sequence (RefSeq transcript) :SRS	NM_004095
Reference transcript : Entrez	NM_004095
RefSeq genomic : SRS	AC_000051 AC_000140 NC_000008 NT_007995 NW_001839128 NW_923907
RefSeq genomic : Entrez	AC_000051 AC_000140 NC_000008 NT_007995 NW_001839128 NW_923907
Consensus coding sequences : CCDS NCBI	EIF4EBP1
Cluster EST : Unigene	Hs.411641 [SRS] Hs.411641 [NCBI]
Alternative Splicing : Fast-db (Paris)	3791
	Protein : pattern, domain, 3D structure
Protein :	Q13541 (SRS) Q13541 (Expasy) Q13541 (Uniprot)

UniProt/SwissProt	
With graphics : InterPro	Q13541
Splice isoforms : VarSplice FASTA	Q13541(VarSplice FASTA)
Domains : Interpro (SRS)	EIF4EBP
Domains : Interpro (EBI)	EIF4EBP
Related proteins : CluSTr	Q13541
Domain families : Pfam SRS	eIF_4EBP (PF05456)
Domain families : Pfam Sanger	eIF_4EBP (PF05456)
Domain families : Pfam NCBI	pfam05456
Blocks (Seattle)	Q13541
Crystal structure of protein : PDB SRS	1WKW 2JGB 2JGC 2V8W 2V8X 2V8Y
Crystal structure of protein : PDBSum	1WKW 2JGB 2JGC 2V8W 2V8X 2V8Y
Crystal structure of protein : IMB	1WKW 2JGB 2JGC 2V8W 2V8X 2V8Y
Crystal structure of protein : PDB RSDB	1WKW 2JGB 2JGC 2V8W 2V8X 2V8Y
HPRD	03746
	Protein Interaction databases
DIP (DOE-UCLA)	Q13541
IntAct (EBI)	Q13541
	Polymorphism : SNP, mutations, diseases
Single Nucleotide Polymorphism (SNP) : dbSNP NCBI	EIF4EBP1
SNP : GeneSNP Utah	EIF4EBP1
SNP : HGBase	EIF4EBP1
Genetic variants : HAPMAP	EIF4EBP1
Somatic Mutations in Cancer : COSMIC	EIF4EBP1
Mutations and Diseases : HGMD	EIF4EBP1
Hereditary diseases : OMIM	602223
Hereditary diseases : GENETests	602223
Diseases : Genetic Association	EIF4EBP1
	General knowledge
Homologs : HomoloGene	EIF4EBP1
Homology/Alignments : Family Browser UCSC	EIF4EBP1
Phylogenetic Trees/Animal Genes :	EIF4EBP1

TreeFam	
Chemical/Protein Interactions : CTD	1978
Keywords Ontology : AmiGO	protein binding cytosol eukaryotic initiation factor 4E binding insulin receptor signaling pathway negative regulation of translational initiation
Keywords Ontology : EGO-EBI	protein binding cytosol eukaryotic initiation factor 4E binding insulin receptor signaling pathway negative regulation of translational initiation
Pathways : BIOCARTA	Regulation of eIF4e and p70 S6 Kinase [Genes] Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway [Genes] mTOR Signaling Pathway [Genes]
Pathways : KEGG	mTOR signaling pathwayInsulin signaling pathway
	Other databases
	Probes
Probes : Imagenes	EIF4EBP1 Related clones (RZPD - Berlin)
	Literature
PubMed	**97 Pubmed reference(s) in Entrez**
PubGene	EIF4EBP1

Bibliography

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function.
Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC Jr, Sonenberg N.
Nature. 1994 Oct 27;371(6500):762-7.
PMID 7935836

4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family.
Poulin F, Gingras AC, Olsen H, Chevalier S, Sonenberg N.
J Biol Chem. 1998 May 29;273(22):14002-7.
PMID 9593750

Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif.
Tee AR, Proud CG.
Mol Cell Biol. 2002 Mar;22(6):1674-83.
PMID 11865047

ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1.
Rolli-Derkinderen M, Machavoine F, Baraban JM, Grolleau A, Beretta L, Dy M.
J Biol Chem. 2003 May 23;278(21):18859-67. Epub 2003 Mar 4.
PMID 12618431

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.
Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA.
Cancer Cell. 2004 Jun;5(6):553-63.
PMID 15193258

mTOR-mediated regulation of translation factors by amino acids.
Proud CG.
Biochem Biophys Res Commun. 2004 Jan 9;313(2):429-36.
PMID 14684180

Comprehensive profiling of 8p11-12 amplification in breast cancer.
Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F, Esteyries S, Adelaide J, Esterni B, Henry C, Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauffret E, Jacquemier J, Bertucci F, Birnbaum D, Theillet C, Chaffanet M.
Mol Cancer Res. 2005 Dec;3(12):655-67.
PMID 16380503

Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG.
Mol Cell Biol. 2005 Apr;25(7):2558-72.
PMID 15767663

Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.
Connolly E, Braunstein S, Formenti S, Schneider RJ.
Mol Cell Biol. 2006 May;26(10):3955-65.
PMID 16648488

Different roles for the TOS and RAIP motifs of the translational regulator protein 4E-BP1 in the association with raptor and phosphorylation by mTOR in the regulation of cell size.
Eguchi S, Tokunaga C, Hidayat S, Oshiro N, Yoshino K, Kikkawa U, Yonezawa K.
Genes Cells. 2006 Jul;11(7):757-66.
PMID 16824195

Interferon-alpha induces sensitization of cells to inhibition of protein synthesis by tumour necrosis factor-related apoptosis-inducing ligand.
Jeffrey IW, Elia A, Bornes S, Tilleray VJ, Gengatharan K, Clemens MJ.
FEBS J. 2006 Aug;273(16):3698-708.
PMID 16911520

Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control.
Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, Lambin P, Koumenis C, Sonenberg N, Wouters BG.
EMBO J. 2006 Mar 8;25(5):1114-25. Epub 2006 Feb 9.
PMID 16467844

Regulation of protein synthesis by insulin.
Proud CG.
Biochem Soc Trans. 2006 Apr;34(Pt 2):213-6.
PMID 16545079

Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells.
Tilleray V, Constantinou C, Clemens MJ.
FEBS Lett. 2006 Mar 20;580(7):1766-70. Epub 2006 Feb 21.
PMID 16504179

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.
Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon y Cajal S.
Cancer Res. 2007 Aug 15;67(16):7551-5.
PMID 17699757

A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.
Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ.
Mol Cell. 2007 Nov 9;28(3):501-12.
PMID 17996713

Regulation of translation factors eIF4GI and 4E-BP1 during recovery of protein synthesis from inhibition by p53.
Constantinou C, Clemens MJ.
Cell Death Differ. 2007 Mar;14(3):576-85. Epub 2006 Sep 22.
PMID 16990847

Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E.
Culjkovic B, Topisirovic I, Borden KL.
Cell Cycle. 2007 Jan 1;6(1):65-9. Epub 2007 Jan 11.
PMID 17245113

Regulation of muscle protein synthesis during sepsis and inflammation.
Lang CH, Frost RA, Vary TC.
Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E453-9. Epub 2007 May 15.
PMID 17505052

Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2.
Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N.
J Clin Invest. 2007 Feb;117(2):387-96.
PMID 17273556

FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle.
Southgate RJ, Neill B, Prelovsek O, El-Osta A, Kamei Y, Miura S, Ezaki O, McLoughlin TJ, Zhang W, Unterman TG, Febbraio MA.
J Biol Chem. 2007 Jul 20;282(29):21176-86. Epub 2007 May 17.
PMID 17510058

Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1.
Averous J, Fonseca BD, Proud CG.
Oncogene. 2008 Feb 14;27(8):1106-13. Epub 2007 Aug 27.
PMID 17724476

Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1.
Azar R, Najib S, Lahlou H, Susini C, Pyronnet S.
Cell Mol Life Sci. 2008 Oct;65(19):3110-7.
PMID 18810319

Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival.
Barnhart BC, Lam JC, Young RM, Houghton PJ, Keith B, Simon MC.
Cancer Biol Ther. 2008 Sep;7(9):1441-9. Epub 2008 Sep 11.
PMID 18708753

Activation of p53 stimulates proteasome-dependent truncation of eIF4E-binding protein 1 (4E-BP1).
Constantinou C, Elia A, Clemens MJ.
Biol Cell. 2008 May;100(5):279-89.
PMID 18021075

Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1.
Elia A, Constantinou C, Clemens MJ.
Oncogene. 2008 Jan 31;27(6):811-22. Epub 2007 Jul 23.
PMID 17653084

Analysis of the regulatory motifs in eukaryotic initiation factor 4E-binding protein 1.
Lee VH, Healy T, Fonseca BD, Hayashi A, Proud CG.
FEBS J. 2008 May;275(9):2185-99. Epub 2008 Apr 1.
PMID 18384376

The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and

hypoxia through changes in mRNA translation efficiency.
Magagnin MG, van den Beucken T, Sergeant K, Lambin P, Koritzinsky M, Devreese B, Wouters BG.
Proteomics. 2008 Mar;8(5):1019-28.
PMID 18219697

Impaired myelopoiesis in mice lacking the repressors of translation initiation, 4E-BP1 and 4E-BP2.
Olson KE, Booth GC, Poulin F, Sonenberg N, Beretta L.
Immunology. 2008 Oct 31. [Epub ahead of print]
PMID 19175792

Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs.
Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N.
RNA. 2008 Jul;14(7):1318-27. Epub 2008 May 30.
PMID 18515545

ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress.
Yamaguchi S, Ishihara H, Yamada T, Tamura A, Usui M, Tominaga R, Munakata Y, Satake C, Katagiri H, Tashiro F, Aburatani H, Tsukiyama-Kohara K, Miyazaki J, Sonenberg N, Oka Y.
Cell Metab. 2008 Mar;7(3):269-76.
PMID 18316032

REVIEW articles *automatic* search in PubMed
Last year publications *automatic* search in PubMed

Search in all EBI NCBI

Contributor(s)

Written 02-2009 Michael Clemens, Mark Coldwell
Dept. of Chemistry and Biochemistry, School of Life Sciences, University of Sussex and Division of Basic Medical Sciences, St George's, University of London, United Kingdom (Michael Clemens); School of Biological Sciences, University of Southampton, United Kingdom (Mark Coldwell)

Citation

This paper should be referenced as such :
Clemens M, Coldwell M . EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1).
Atlas Genet Cytogenet Oncol Haematol. February 2009 .
URL : http://AtlasGeneticsOncology.org/Genes/EIF4EBP1ID40432ch8p12.html
© Atlas of Genetics and Cytogenetics in Oncology and Haematology